MA26586A1 - Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant - Google Patents

Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant

Info

Publication number
MA26586A1
MA26586A1 MA25396A MA25396A MA26586A1 MA 26586 A1 MA26586 A1 MA 26586A1 MA 25396 A MA25396 A MA 25396A MA 25396 A MA25396 A MA 25396A MA 26586 A1 MA26586 A1 MA 26586A1
Authority
MA
Morocco
Prior art keywords
treatment
compositions containing
sexual dysfunction
pharmaceutical combination
containing same
Prior art date
Application number
MA25396A
Other languages
English (en)
Inventor
Grant Wyllie Michael
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22090927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26586A1 publication Critical patent/MA26586A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA25396A 1997-12-16 1998-12-15 Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant MA26586A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6974197P 1997-12-16 1997-12-16

Publications (1)

Publication Number Publication Date
MA26586A1 true MA26586A1 (fr) 2004-12-20

Family

ID=22090927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25396A MA26586A1 (fr) 1997-12-16 1998-12-15 Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant

Country Status (37)

Country Link
EP (1) EP1037616B1 (fr)
JP (2) JP2002508315A (fr)
KR (1) KR20010033092A (fr)
CN (1) CN1282248A (fr)
AP (1) AP915A (fr)
AR (1) AR016433A1 (fr)
AT (1) ATE318602T1 (fr)
AU (1) AU759825B2 (fr)
BG (1) BG104528A (fr)
BR (1) BR9813699A (fr)
CA (1) CA2314993A1 (fr)
CO (1) CO4810381A1 (fr)
CZ (1) CZ20002199A3 (fr)
DE (1) DE69833671T2 (fr)
DZ (1) DZ2675A1 (fr)
EA (1) EA200000526A1 (fr)
ES (1) ES2258300T3 (fr)
GT (1) GT199800177A (fr)
HN (1) HN1998000174A (fr)
HR (1) HRP20000407A2 (fr)
HU (1) HUP0100705A3 (fr)
IL (1) IL136515A0 (fr)
IS (1) IS5504A (fr)
MA (1) MA26586A1 (fr)
NO (1) NO20003065L (fr)
NZ (1) NZ504487A (fr)
OA (1) OA11423A (fr)
PA (1) PA8462801A1 (fr)
PE (1) PE20000011A1 (fr)
PL (1) PL341575A1 (fr)
SK (1) SK8782000A3 (fr)
TN (1) TNSN98227A1 (fr)
TR (1) TR200001733T2 (fr)
UY (1) UY25300A1 (fr)
WO (1) WO1999030697A2 (fr)
YU (1) YU33700A (fr)
ZA (1) ZA9811507B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19844162A1 (de) * 1998-09-25 2000-03-30 Udo Dunzendorfer Medikamentenkombinationen zur Therapie der erektilen Dysfunktion
WO2000053148A2 (fr) * 1999-03-08 2000-09-14 Merck & Co., Inc. Procedes et compositions pour le traitement de la dyserection
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
EA004872B1 (ru) * 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
DE60113290D1 (de) * 2000-11-17 2005-10-13 Warner Lambert Co Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2007056457A2 (fr) 2005-11-09 2007-05-18 Combinatorx, Incorporated Procedes, compositions et kits pour le traitement de pathologies
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN101781302B (zh) * 2009-05-31 2013-07-10 段波 一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2014055801A1 (fr) 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878182B (en) * 1986-11-05 1988-05-02 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DK0459666T3 (da) * 1990-05-31 1994-12-05 Pfizer Lægemidler mod impotens
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
AU9455898A (en) 1999-07-05
ZA9811507B (en) 2000-06-19
BR9813699A (pt) 2000-10-10
NZ504487A (en) 2002-11-26
EP1037616A2 (fr) 2000-09-27
CZ20002199A3 (cs) 2001-10-17
KR20010033092A (ko) 2001-04-25
DE69833671D1 (de) 2006-04-27
CN1282248A (zh) 2001-01-31
AP9801414A0 (en) 1998-12-31
NO20003065D0 (no) 2000-06-15
PA8462801A1 (es) 2000-05-24
HN1998000174A (es) 1999-01-08
DE69833671T2 (de) 2006-11-30
GT199800177A (es) 2000-05-02
PE20000011A1 (es) 2000-01-18
HUP0100705A3 (en) 2001-12-28
HUP0100705A2 (hu) 2001-08-28
CA2314993A1 (fr) 1999-06-24
YU33700A (sh) 2004-05-12
EA200000526A1 (ru) 2000-12-25
TNSN98227A1 (fr) 2005-03-15
AR016433A1 (es) 2001-07-04
DZ2675A1 (fr) 2003-03-29
ES2258300T3 (es) 2006-08-16
WO1999030697A2 (fr) 1999-06-24
JP2007332156A (ja) 2007-12-27
IL136515A0 (en) 2001-06-14
SK8782000A3 (en) 2002-03-05
HRP20000407A2 (en) 2000-10-31
PL341575A1 (en) 2001-04-23
AU759825B2 (en) 2003-05-01
JP2002508315A (ja) 2002-03-19
IS5504A (is) 2000-05-19
UY25300A1 (es) 2000-12-29
NO20003065L (no) 2000-08-15
EP1037616B1 (fr) 2006-03-01
CO4810381A1 (es) 1999-06-30
BG104528A (en) 2001-02-28
OA11423A (en) 2004-04-21
AP915A (en) 2000-12-18
TR200001733T2 (tr) 2000-11-21
ATE318602T1 (de) 2006-03-15
WO1999030697A3 (fr) 1999-08-26

Similar Documents

Publication Publication Date Title
MA26586A1 (fr) Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
MA26568A1 (fr) Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
EP0801646A4 (fr) Compositions pharmaceutiques pour la prevention et le traitement de maladies du systeme nerveux central
DZ2538A1 (fr) Tartrate d'un dipeptide substitué procédé pour sa préparation et compositions pharmaceutiques le contenant.
EP0707446A4 (fr) Compositions pharmaceutiques et leur utilisation pour le traitement d'affections neurologiques et de symptomologies a etiologies associees
MA26426A1 (fr) Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant
FR2742657B1 (fr) Compositions pour le traitement des matieres keratiniques contenant l'association d'un polymere polyampholyte et d'un polymere cationique
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
EP0770394A3 (fr) Composition contenant des extraits de plantes pour le traitement de la mastite bovine
TNSN97125A1 (fr) Composes furanne-nitrone
FR2758465B1 (fr) Composition pour le traitement de l'amiante
FR2752422B1 (fr) Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FR2741355B1 (fr) Composition pour le traitement d'objets que l'on souhaite nettoyer et/ou desinfecter
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
BE887639A (fr) Compositions pharmaceutiques pour le traitement de l'hyperplasie prostatique benigne
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
EP0719552A3 (fr) Compositions pharmaceutique contenant un dérivé quinoné ou hydroquinone pour le traitement des dermatites
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
EP0859761A4 (fr) 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques
EP0800396A4 (fr) Traitement d'etats d'hyperandrogenie
EP0969852A4 (fr) Therapie par combinaison d'agents pour le traitement du diabete et de l'obesite